27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
There is consistent evidence supporting an association between AF and increased incidence of dementia in patients with stroke whereas there remains considerable uncertainty about any link in the broader population. 5 key findings →
Design: meta-analysis Participants: 46,637 Evidence: high
Full summary, score breakdown and related studies → Original source
Presence and severity of WMH are associated with substantially increased risk of dementia, functional impairment, stroke recurrence, and mortality after ischemic stroke. 5 key findings →
Design: meta-analysis Participants: 104 Evidence: high
Full summary, score breakdown and related studies → Original source
Our objectives were to investigate the utility of the Hachinski Ischemic Score (HIS) in differentiating patients with pathologically verified Alzheimer's disease (AD), multi-infarct dementia (MID), and "mixed" (AD plus cerebrovascular disease) dementia, and to identify the specific items of the HIS that best discriminate those dementia subtypes. 4 key findings →
Design: meta-analysis Participants: 312 Evidence: high
Full summary, score breakdown and related studies → Original source
Our data show that elderly patients with DM without dementia have accelerated progression of brain atrophy with significant consequences in cognition compared to subjects without DM. 5 key findings →
Design: randomized controlled trial Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source
Statin users were less likely to have incident dementia/cognitive impairment without dementia during a 5-year follow-up. 2 key findings →
Design: cohort study Participants: 1,674 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hypertension after age 65 years is not associated with AD and does not adversely affect memory, language, or general cognitive function. 5 key findings →
Design: longitudinal study Participants: 1,259 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the absence of clinical stroke, people with incident atrial fibrillation are likely to reach thresholds of cognitive impairment or dementia at earlier ages than people with no history of atrial fibrillation. 2 key findings →
Design: longitudinal study Participants: 5,150 Evidence: moderate
Full summary, score breakdown and related studies → Original source
One hundred ninety-eight of 229 participants had WMH volumes available at both time-points. 5 key findings →
Design: longitudinal study Participants: 229 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment short of dementia affects nearly one in four community-dwelling elders and is a major risk factor for later development of dementia. 1 key finding →
Design: longitudinal study Participants: 351 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated. 5 key findings →
Participants: 616 Evidence: high
Full summary, score breakdown and related studies → Original source
We included 147,986 participants (Chinese [n = 6,034], Filipino [n = 4,649], Japanese [n = 3,099], South Asian [n = 996], non-Latino White [n = 133,208]); the mean baseline age ranged from 69 to 72 years, and the percentage of female participants ranged from 40% to 63% across groups. 5 key findings →
Design: cohort study Participants: 6,034 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
IL-6, and, to a lesser degree, CRP levels were associated with WMH severity as well as global markers of brain atrophy. 4 key findings →
Design: cross-sectional Participants: 1,316 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The results of this preliminary case-control study suggest that estradiol levels may decline significantly in women in whom AD develops. 5 key findings →
Design: case-control study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cross-sectional analysis of CBF values was carried out among 668 volunteers and patients. 5 key findings →
Design: cross-sectional Participants: 230 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 2,335 participants (mean age 52.3 ± 11.2 years; 56.6% women), CVD risk trajectories over 10 years were classified as accelerated increase (29.2%), moderate increase (30.9%), or stable (39.9%). 5 key findings →
Design: cohort study Participants: 2,335 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We determined the frequency of dementia in a cohort of 251 patients aged greater than or equal to 60 years hospitalized with acute ischemic stroke, based on examinations performed 3 months after stroke onset. 5 key findings →
Participants: 251 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The small effect of VRFs and LAD on WMH suggests that WMH have a large "nonvascular," nonatheromatous etiology. 3 key findings →
Participants: 881 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the Research Article "Magnitude and Time-Course of Dementia Risk in Stroke Survivors: A Population-Wide Matched Cohort Study" by Joundi et al., 1 the keys for Figure 3, A-D should indicate red for "Stroke," "Ischemic Stroke," "ICH," and "Stroke," respectively. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the absence of other prior neurologic insult, both AD and other dementias increase the risk of generalized- and partial-onset unprovoked seizures. 2 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results confirm that vitamin D deficiency is associated with a substantially increased risk of all-cause dementia and Alzheimer disease. 5 key findings →
Participants: 171 Evidence: low
Full summary, score breakdown and related studies → Original source
We used the medical records linkage system for the population of Rochester, Minnesota, to identify persons in the community who had their first cerebral infarct without previous dementia. 2 key findings →
Participants: 971 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The cognitive deficits in VaD and VCI are characterized by disturbance of frontal functions, with less verbal memory impairment. 2 key findings →
Participants: 170 Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolic syndrome is associated with Alzheimer disease in elderly subjects. 5 key findings →
Participants: 959 Evidence: low
Full summary, score breakdown and related studies → Original source
= 0.028), but not with progression of BG-EPVS or WMHs at follow-up. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
= 0.025) over 3 years. NfL was not significantly associated with any MRI cSVD marker. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →